Eton Pharmaceuticals (ETON) to Release Earnings on Thursday

Key Points

• Eton Pharmaceuticals (ETON) is set to announce its Q2 2025 earnings on August 7th, with analysts expecting a loss of ($0.02) per share and revenue of $16.71 million.
• The company's stock has exhibited a 12-month price range between $3.25 and $21.48, and currently has a market cap of $389.43 million.
• Recently, insider David Krempa sold 10,223 shares, reducing his position by 1.64%, while institutional investors have significantly increased their stakes in Eton Pharmaceuticals.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Eton Pharmaceuticals to post earnings of ($0.02) per share and revenue of $16.71 million for the quarter.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The firm had revenue of $17.28 million for the quarter, compared to analyst estimates of $14.33 million. Eton Pharmaceuticals had a negative net margin of 9.49% and a negative return on equity of 3.15%. On average, analysts expect Eton Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Eton Pharmaceuticals Stock Up 1.5%

ETON traded up $0.21 during trading on Monday, reaching $14.34. 109,131 shares of the stock traded hands, compared to its average volume of 364,990. The stock has a market cap of $384.57 million, a price-to-earnings ratio of -79.64 and a beta of 1.13. Eton Pharmaceuticals has a fifty-two week low of $3.25 and a fifty-two week high of $21.48. The company has a debt-to-equity ratio of 1.23, a current ratio of 1.97 and a quick ratio of 1.43. The stock's 50-day simple moving average is $15.29 and its two-hundred day simple moving average is $15.45.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, insider David Krempa sold 16,977 shares of the business's stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $14.92, for a total transaction of $253,296.84. Following the completion of the transaction, the insider owned 629,669 shares of the company's stock, valued at approximately $9,394,661.48. The trade was a 2.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 34,000 shares of company stock worth $504,318. 16.03% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Large investors have recently made changes to their positions in the business. Millennium Management LLC lifted its position in shares of Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company's stock worth $4,620,000 after purchasing an additional 217,042 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company's stock valued at $2,274,000 after acquiring an additional 45,341 shares during the period. Finally, Jane Street Group LLC increased its stake in Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company's stock valued at $1,245,000 after acquiring an additional 31,596 shares during the period. Institutional investors and hedge funds own 27.86% of the company's stock.

Analysts Set New Price Targets

ETON has been the subject of a number of analyst reports. Craig Hallum boosted their price target on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. B. Riley reaffirmed a "buy" rating and issued a $26.00 price target (up previously from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target (up previously from $33.00) on shares of Eton Pharmaceuticals in a research report on Thursday, May 29th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.